Novavax COVID-19 Vaccine Demonstrates 90% Overall Efficacy and 100% Protection Against Moderate and Severe Disease in PREVENT-19 Phase 3 Trial
Go back to Novavax COVID-19 Vaccine Demonstrates 90% Overall Efficacy and 100% Protection Against Moderate and Severe Disease in PREVENT-19 Phase 3 Trial| Novavax, Inc. (NASDAQ: NVAX) | Delayed: 3.95 -0.2 (4.82%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $4.15 | 52 Week High | $9.23 | |||
| Open | $4.09 | 52 Week Low | $1.16 | |||
| Day High | $4.12 | P/E | N/A | |||
| Day Low | $3.91 | EPS | $-0.30 | |||
| Volume | 1,936,081 | |||||
